8,456 peer-reviewed studies, each with a short note written from its published abstract: what kind of study it was, who took part, what was measured and what the authors reported. Observational studies show associations, not proof.
2010 / Randomized controlled trial
In 125 pregnant women with low dietary calcium intakes (roughly 350 mg daily), receiving 1,500 mg calcium daily until delivery resulted in lower postpartum hip bone mineral content (-10.7 +/- 3.7%, P = 0.005), bone area (-3.8 +/- 1.9%, P = 0.05), and bone mineral density (-6.9 +/- 2.6%, P = 0.01) across 12 months of lactation compared to placebo. Supplemented mothers also had greater bone mineral reductions at the spine and radius.
Jarjou LM, Laskey MA, Sawo Y, et al. Am J Clin Nutr, 2010. PMID 20554790
2010 / Controlled clinical trial
An eight-month controlled study evaluated the efficacy and safety of Meriva, a curcumin-phosphatidylcholine complex, in 100 osteoarthritis patients. Significant improvements in both clinical endpoints (WOMAC score, Karnofsky Performance Scale Index, and treadmill walking performance) and biochemical endpoints (IL-1beta, IL-6, sCD40L, sVCAM-1, and ESR) were observed for Meriva compared to the control group. The authors reported excellent tolerability.
Belcaro G, Cesarone MR, Dugall M, et al. Altern Med Rev, 2010. PMID 21194249
2009 / Intervention study with 3 groups
Researchers measured blood lead levels and bone turnover in 73 women before and after 6 months of severe weight loss (S-WL), moderate weight loss (M-WL), or weight maintenance (WM). After severe weight loss (-37.4 +/- 9.3 kg, n=17), blood lead increased by 2.1 +/- 3.9 microg/dl (P < 0.05), reaching levels of 1.3-12.5 microg/dl. M-WL (-5.6 +/- 2.7 kg, n=39) and WM (0.3 +/- 1.3 kg, n=17) did not significantly increase blood lead levels (changes of 0.5 +/- 3.2 and 0.0 +/- 0.7 microg/dl, respectively). Bone turnover markers increased only with severe weight loss and directly correlated with weight loss.
Riedt CS, Buckley BT, Brolin RE, et al. J Expo Sci Environ Epidemiol, 2009. PMID 18322449
2009 / Randomized controlled trial (subgroup analyses)
Researchers randomized 222 patients with hip osteoarthritis to receive either 1500 mg of oral glucosamine sulphate or placebo once daily for 2 years. Subgroup analyses examined radiographic severity, localized versus generalized osteoarthritis, pain level, medication use, baseline joint space width, and concomitant knee osteoarthritis. In the predefined subgroups, WOMAC pain, function, and joint space narrowing outcomes were similar between the glucosamine sulphate and placebo groups.
Rozendaal RM, Uitterlinden EJ, van Osch GJ, et al. Osteoarthritis Cartilage, 2009. PMID 18848470
2009 / Randomized, double-blind, placebo-controlled trial
In an international trial, 622 patients with knee osteoarthritis were randomized to receive 800 mg chondroitins 4 and 6 sulfate (CS) or placebo once daily for 2 years. Intent-to-treat analysis showed a significant reduction in minimum joint space width (JSW) loss in the CS group (-0.07 +/- 0.03 mm) compared to placebo (-0.31 +/- 0.04 mm; P < 0.0001). The proportion of patients with radiographic progression >= 0.25 mm was lower with CS (28% vs. 41%, P < 0.0005; relative risk reduction 33%), and pain improved significantly faster in the CS group (P < 0.01) with no differences in safety.
Kahan A, Uebelhart D, De Vathaire F, et al. Arthritis Rheum, 2009. PMID 19180484
2009 / Prospective comparative study with matched groups
A prospective study followed 37 inactive Crohn's disease patients in two matched groups receiving either active or plain vitamin D. At six weeks, the active form was linked to lower disease activity index values (69.44 vs 57.0) and C-reactive protein (15.8 vs 7.81 mmol/L, P < 0.05). Markers of bone turnover also decreased and osteoprotegerin rose with the active form. These biochemical changes were stronger at three months but disappeared by month 12.
Miheller P, Muzes G, Hritz I, et al. Inflamm Bowel Dis, 2009. PMID 19408329
2009 / Randomized controlled trial
A randomized trial enrolled 107 patients with primary knee osteoarthritis and assigned them to receive either 2 g of Curcuma domestica extract daily or 800 mg of ibuprofen daily for 6 weeks. Both interventions yielded significant improvements compared to baseline in pain during walking and stair climbing, as well as time spent during a 100-m walk and stair traversal. Adverse event frequencies did not differ significantly between treatments (33.3% vs. 44.2%, p = 0.36).
Kuptniratsaikul V, Thanakhumtorn S, Chinswangwatanakul P, et al. J Altern Complement Med, 2009. PMID 19678780
2009 / Intervention trial
Twenty-six patients with monoclonal gammopathy of undefined significance (MGUS) were administered 4 grams/day of oral curcumin to examine its effects on plasma cells and osteoclasts. Among patients with a paraprotein level >20 g/L, 50% (5 of 10) experienced a 12% to 30% reduction in paraprotein levels during curcumin therapy. Additionally, 27% of patients on curcumin demonstrated a >25% decrease in the bone turnover marker urinary N-telopeptide of type I collagen.
Golombick T, Diamond TH, Badmaev V, et al. Clin Cancer Res, 2009. PMID 19737963
2008 / Randomized controlled trial
In a five-year randomized controlled trial of 1,471 postmenopausal women, adjudicated myocardial infarction occurred in 21 women receiving calcium versus 10 receiving placebo (relative risk 2.12, 95% CI 1.01 to 4.47). The composite endpoint of myocardial infarction, stroke, or sudden death occurred in 51 calcium recipients versus 35 placebo recipients (relative risk 1.47, 95% CI 0.97 to 2.23). Adding hospital data yielded a composite rate ratio of 1.43 (95% CI 1.01 to 2.04).
Bolland MJ, Barber PA, Doughty RN, et al. BMJ, 2008. PMID 18198394
2008 / Randomized controlled trial
Circulating 25-hydroxyvitamin D was measured in 184 patients with diffuse musculoskeletal pain and 104 osteoarthritis controls, showing no significant difference between groups (29.2 +/- 13.0 vs 28.8 +/- 10.5 ng/mL, P = 0.78). Fifty patients with levels of 20 ng/mL or lower were randomized to ergocalciferol (50,000 IU weekly) or placebo for 3 months. Vitamin D treatment did not significantly improve pain compared to baseline (P = 0.73) or compared to placebo at 3 months (P = 0.12).
Warner AE, Arnspiger SA J Clin Rheumatol, 2008. PMID 18431091
2008 / 24-month double-blind placebo-controlled randomized trial
In the GAIT trial, 572 patients with knee osteoarthritis were randomized to receive glucosamine (500 mg 3 times daily), chondroitin sulfate (400 mg 3 times daily), their combination, celecoxib (200 mg daily), or placebo over 24 months. Adjusted mean joint space width (JSW) loss at 2 years in the placebo group was 0.166 mm, and no statistically significant difference in mean JSW loss was seen in any treatment group compared with placebo. A trend toward improvement was observed in Kellgren/Lawrence grade 2 knees, but not grade 3 knees. The authors noted study power was diminished by limited sample size, variance of JSW measurement, and smaller than expected JSW loss.
Sawitzke AD, Shi H, Finco MF, et al. Arthritis Rheum, 2008. PMID 18821708
2007 / Randomized placebo-controlled trial
A randomized placebo-controlled trial evaluated daily administration of 1,500 mg glucosamine hydrochloride versus placebo for 12 weeks alongside conventional medication in 51 rheumatoid arthritis patients. Significant improvements were not observed for joint counts, ACR20 responder rates, ESR, or CRP levels. However, the face scale and visual analogue scale for pain significantly favored the glucosamine group, and serum MMP-3 levels decreased. Patient self-evaluations and physician global evaluations showed noticeable symptom improvements, leading authors to conclude that glucosamine seemed to exert some symptomatic effects without conventional antirheumatic effects.
Nakamura H, Masuko K, Yudoh K, et al. Rheumatol Int, 2007. PMID 16953394
2007 / Randomized controlled trial
In a 1-year randomized controlled trial, 149 healthy women aged 70-78 were assigned to resistance training (RES), balance-jumping training (BAL), a combination (COMB), or control (CON). Self-rated physical functioning showed a mean inter-group difference of 10% (95% CI: 0-22%) favoring COMB versus CON. Leg extensor force increased more in RES (14%; 4-25%) and COMB (13%; 3-25%) compared with CON, while dynamic balance improved in BAL (6%; 1-11%) and COMB (8%; 3-12%). There were no inter-group differences in BMC at the proximal femur, but in COMB women training at least twice a week, tibial shaft structure weakened 2% (0-4%) less than in the CON group.
Karinkanta S, Heinonen A, Sievänen H, et al. Osteoporos Int, 2007. PMID 17103296
2007 / Randomized controlled trial
A randomized, double-blind, placebo-controlled trial evaluated 9,440 adults aged 75 and older who received an annual intramuscular injection of 300,000 IU vitamin D2 or placebo over 3 years. Vitamin D did not significantly reduce non-vertebral fractures (HR 1.09, 95% CI 0.93-1.28) or falls (HR 0.98, 95% CI 0.93-1.04). However, hip fracture risk was increased in the vitamin D group (HR 1.49, 95% CI 1.02-2.18).
Smith H, Anderson F, Raphael H, et al. Rheumatology (Oxford), 2007. PMID 17998225
2006 / Pharmacokinetic intervention study
Eighteen subjects with osteoarthritis were administered 1,500 mg of commercial glucosamine sulphate after an overnight fast, with serum collected over 3 hours (and up to 8 hours in two subjects). Baseline serum glucosamine was below the 0.5 mumol/l detection limit in all subjects. After ingestion, glucosamine was detected in 17 of 18 subjects, rising at 30-45 minutes to a maximum at 90-180 minutes with a range of 1.9-11.5 micromol/l (0.34-2 microg/ml). The authors note this peak concentration is far lower than levels claimed to have in vitro effects.
Biggee BA, Blinn CM, McAlindon TE, et al. Ann Rheum Dis, 2006. PMID 16079170
2006 / Multicenter, double-blind, randomized controlled trial
In the GAIT trial, 1,583 patients with symptomatic knee osteoarthritis were randomized to receive 1500 mg glucosamine, 1200 mg chondroitin sulfate, both, 200 mg celecoxib, or placebo daily for 24 weeks. Overall, response rates were not significantly higher than placebo (60.1%) for glucosamine (+3.9 percentage points, P=0.30), chondroitin sulfate (+5.3 percentage points, P=0.17), or the combination (+6.5 percentage points, P=0.09), whereas celecoxib was significantly higher (+10.0 percentage points, P=0.008). In an exploratory subgroup with moderate-to-severe baseline pain, combined therapy had a significantly higher response rate than placebo (79.2% vs. 54.3%, P=0.002).
Clegg DO, Reda DJ, Harris CL, et al. N Engl J Med, 2006. PMID 16495392
2006 / Randomized controlled trial
A randomized trial of 48 adults aged 57 +/- 3 years evaluated 1-year changes in bone mineral density across caloric restriction, exercise, or a healthy lifestyle control. Caloric restriction decreased bone mineral density at the total hip (-2.2% +/- 3.1%), intertrochanter (-2.1% +/- 3.4%), and spine (-2.2% +/- 3.3%) compared to controls. Conversely, exercise-induced weight loss did not result in bone loss at any site despite comparable reductions in body weight.
Villareal DT, Fontana L, Weiss EP, et al. Arch Intern Med, 2006. PMID 17159017
2005 / Randomized crossover trial
Thirteen healthy women completed a randomized crossover study comparing 10 days of a moderate-protein diet (1.0 g/kg) to a high-protein diet (2.1 g/kg) following a 2-week lead-in diet. Intestinal calcium absorption increased on the high-protein diet compared to the moderate-protein diet (26.2 +/- 1.9% vs. 18.5 +/- 1.6%, P < 0.0001), as did urinary calcium (5.23 +/- 0.37 vs. 3.57 +/- 0.35 mmol/d, P < 0.0001). The high-protein diet significantly reduced the fraction of urinary calcium of bone origin, showed a nonsignificant trend toward lower bone turnover, and had no effect on net bone balance.
Kerstetter JE, O'Brien KO, Caseria DM, et al. J Clin Endocrinol Metab, 2005. PMID 15546911
2005 / Randomized controlled trial
Eighty obese patients with knee osteoarthritis were randomized to an intensive low-energy diet (3.4 MJ/day) with weekly counseling or a control diet (5 MJ/day) with written guidance. The low-energy group lost 11.1% of body weight compared to 4.3% in controls (difference 6.8%, 95% CI: 5.5 to 8.1%, P < 0.0001). Total WOMAC scores improved in the low-energy cohort (mean difference -219.3 mm, P = 0.005), and every 1% reduction in body fat predicted a 9.4% improvement in symptoms.
Christensen R, Astrup A, Bliddal H Osteoarthritis Cartilage, 2005. PMID 15639633
2005 / Randomized controlled trial
In a randomized trial of 354 females enrolled at pubertal stage 2, participants received approximately 670 mg/day of supplemental calcium or placebo over up to 7 years. Supplementation significantly increased all measured bone mineral density endpoints at year 4. By year 7, the benefit vanished for total-body and distal radius bone mineral density, though significant effects remained at metacarpal sites.
Matkovic V, Goel PK, Badenhop-Stevens NE, et al. Am J Clin Nutr, 2005. PMID 15640478
2005 / Randomized, double-blind, placebo-controlled trial
In a randomized, double-blind, placebo-controlled trial, 300 patients with knee osteoarthritis were assigned to receive 800 mg chondroitin sulfate (CS) or placebo once daily for 2 years. Patients receiving placebo experienced a mean joint space loss of 0.14 +/- 0.61 mm after 2 years (P = 0.001 compared with baseline), whereas patients receiving CS showed no change (0.00 +/- 0.53 mm; P not significant compared with baseline). The difference in joint space loss between the two groups was significant for mean joint space width (0.14 +/- 0.57 mm; P = 0.04) and minimum joint space width (0.12 +/- 0.52 mm; P = 0.05). There was no significant symptomatic effect on pain or function, and CS was well tolerated.
Michel BA, Stucki G, Frey D, et al. Arthritis Rheum, 2005. PMID 15751094
2005 / Randomized controlled trial
A randomized controlled trial evaluated pubertal adolescents given 8 g daily of mixed inulin-type fructans or maltodextrin placebo. Calcium absorption was significantly higher with fructans at eight weeks (difference 8.5%, P < 0.001) and one year (difference 5.9%, P = 0.04). After one year, the fructan group gained significantly more whole-body bone mineral content (difference 35 g, P = 0.03) and bone mineral density (difference 0.015 g/cm2, P = 0.01).
Abrams SA, Griffin IJ, Hawthorne KM, et al. Am J Clin Nutr, 2005. PMID 16087995
2005 / Three-way crossover trial
Twenty young women participated in a crossover trial evaluating fractional calcium absorption from 250 mg of calcium supplied as cow's milk or fortified soymilks. Absorption from calcium carbonate-fortified soymilk (0.211 +/- 0.057) did not differ significantly from cow's milk (0.217 +/- 0.040). Both provided significantly higher calcium absorption than tricalcium phosphate-fortified soymilk (0.181 +/- 0.039, P < 0.05).
Zhao Y, Martin BR, Weaver CM J Nutr, 2005. PMID 16177199
2004 / Randomized controlled trial
In an 89-woman randomized trial lasting two years, researchers examined the effects of soymilk with isoflavones, transdermal progesterone, or both on bone mineral density. Lumbar spine bone mineral density changes did not differ from zero with isoflavone soymilk (+1.1%) or progesterone alone (-1.1%), but controls lost -4.2% and combined treatment lost -2.8%. Femoral neck bone mineral density did not change significantly in any group.
Lydeking-Olsen E, Beck-Jensen JE, Setchell KD, et al. Eur J Nutr, 2004. PMID 15309425